New Strength of Verapamil Tablets Launched

Article

Heritage Pharmaceuticals Inc has launched verapamil 40 mg immediate-release tablets for the treatment of angina, arrhythmias, and essential hypertension.

Heritage Pharmaceuticals Inc has launched verapamil 40 mg immediate-release tablets for the treatment of angina, arrhythmias, and essential hypertension.

Verapamil is the generic equivalent to the calcium channel blocker Calan.

Already, Heritage offers the tablets in 80 mg and 120 mg strength.

The medicine can be taken alone or with other medications to reduce the risk of irregular heartbeat, according to the US National Library of Medicine.

Verapamil works by relaxing the blood vessels in the body. In turn, the heart does not have to work as hard to pump blood. Furthermore, the medication can boost the supply of blood and oxygen to the heart.

Adverse effects include constipation, heartburn, dizziness, and headache.

However, some more severe adverse effects have been noted, including fainting, difficulty breathing, blurred vision, and nausea. These symptoms should be immediately reported to a medical professional.

While verapamil is commonly prescribed to treat high blood pressure and angina, it may be given to patients for other types of cardiovascular conditions.

For the fiscal year ending in October 2015, the US market for verapamil was approximately $1.9 million, according to IMS Health.

Related Videos
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin - stock.adobe.com
Image credit: motortion | stock.adobe.com - Young depressed woman talking to lady psychologist during session, mental health
Image credit:  JPC-PROD | stock.adobe.com - Choosing method of contraception : Birth control pills, an injection syringe, condom, IUD-method, on grey
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin - stock.adobe.com
Health care provider examining MRI images of patient with multiple sclerosis -- Image credit: New Africa | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.